World of DTC Marketing
DECEMBER 10, 2020
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Say goodbye to all the supposed goodwill.
World of DTC Marketing
AUGUST 12, 2022
Among the 25 worldwide companies that spend the most on research and development—all more than $5 billion a year—seven are pharmaceutical manufacturers, but eight are automobile or automobile parts companies with profit margins under 10 percent. It also raises healthcare costs for public and private insurers alike.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Eversana Intouch
DECEMBER 13, 2024
Correspondingly, pharmaceutical manufacturers spend exponentially more on marketing healthcare, including more than $6 billion annually on direct-to-consumer advertising. marketers, we have an ethical duty to position purposeful marketing initiatives not only for the insured American, but for humanity.
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).
Impetus Digital
AUGUST 2, 2024
Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology.
PM360
AUGUST 9, 2022
The combined solution enables health plans and self-insured employers to realize immediate pharmacy cost savings and near-term medical cost reductions by integrating Levrx’s plan-specific and real-time prescription insights into the Adhere Platform medication optimization offerings. Chief Marketing Officer, AdhereHealth.
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).
Expert insights. Personalized for you.
181 
Let's personalize your content